<![CDATA[KBI Biopharma, Inc. 보도자료 - 뉴스와이어]]>https://www.newswire.co.kr/?md=A10&act=article&no=43001>Thu, 30 Apr 2026 09:10:57 +0900Copyright (c) 2004~2026 Korea Newswire All rights reservedko-KR<![CDATA[Following a Successful FDA Inspection, KBI Biopharma Extends and Expands Commercial Contract with Leading Global Pharmaceutical Company]]>https://www.newswire.co.kr/newsRead.php?no=993973Thu, 25 Jul 2024 10:00:00 +0900<![CDATA[KBI 바이오파마, FDA 실사 성공 후 일류 글로벌 제약사와 상업적 계약 연장 및 확대 발표]]>https://www.newswire.co.kr/newsRead.php?no=993975Thu, 25 Jul 2024 10:00:00 +0900<![CDATA[KBI Biopharma Appoints Jean-Baptiste Agnus as Chief Business Officer]]>https://www.newswire.co.kr/newsRead.php?no=987886Tue, 16 Apr 2024 11:40:00 +0900<![CDATA[KBI 바이오파마, 장-밥티스트 아그누스를 최고사업책임자로 임명]]>https://www.newswire.co.kr/newsRead.php?no=987887Tue, 16 Apr 2024 11:40:00 +0900<![CDATA[KBI Biopharma Strengthens Quality and Regulatory Affairs Expertise with Appointment of Chief Quality Officer]]>https://www.newswire.co.kr/newsRead.php?no=987082Tue, 02 Apr 2024 13:50:00 +0900<![CDATA[KBI 바이오파마, 최고품질책임자 임명… 품질 및 규제 업무 전문성 강화]]>https://www.newswire.co.kr/newsRead.php?no=987083Tue, 02 Apr 2024 13:50:00 +0900<![CDATA[KBI Biopharma, Inc. Expands Global Portfolio with Launch of SUREmAb™ for Faster Monoclonal Antibody Development and Manufacturing]]>https://www.newswire.co.kr/newsRead.php?no=974248Wed, 13 Sep 2023 11:20:00 +0900<![CDATA[KBI 바이오파마, 더욱 빠른 단클론 항체 개발 및 제조를 위한 SUREmAb™ 출시로 글로벌 포트폴리오 확장]]>https://www.newswire.co.kr/newsRead.php?no=974250Wed, 13 Sep 2023 11:20:00 +0900<![CDATA[KBI Biopharma, Inc. Continues to Strengthen Leadership and Expertise With Key Executive Appointments]]>https://www.newswire.co.kr/newsRead.php?no=972172Fri, 11 Aug 2023 10:35:00 +0900<![CDATA[KBI 바이오파마, 핵심 임원 임명으로 리더십과 전문성 강화 이어가]]>https://www.newswire.co.kr/newsRead.php?no=972175Fri, 11 Aug 2023 10:35:00 +0900<![CDATA[JSR Life Sciences Announces Operational Consolidation of KBI Biopharma, Inc. and Selexis SA to Operate as one Organization, Providing Seamless Experience for Partners]]>https://www.newswire.co.kr/newsRead.php?no=967987Thu, 01 Jun 2023 14:55:00 +0900<![CDATA[JSR라이프사이언스, KBI바이오파마와 셀렉시스SA의 운영 통합을 통해 하나의 조직으로 파트너에 원활한 환경 제공]]>https://www.newswire.co.kr/newsRead.php?no=967988Thu, 01 Jun 2023 14:55:00 +0900<![CDATA[KBI Biopharma and Selexis SA Appoint J.D. Mowery as CEO]]>https://www.newswire.co.kr/newsRead.php?no=965295Tue, 18 Apr 2023 10:10:00 +0900<![CDATA[KBI 바이오파마-셀렉시스, 최고경영자로 J.D. 모워리 선임]]>https://www.newswire.co.kr/newsRead.php?no=965296Tue, 18 Apr 2023 10:10:00 +0900